Navigation Links
Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated
Date:2/5/2008

lecules. The company is developing versatile product candidates, each potentially capable of treating a number of different diseases and disorders, including chronic pain, muscle spasticity and rigidity, cognitive disorders and xerostomia, or dry mouth. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include statements regarding the potential for tezampanel as a treatment for migraine, the potential for NGX426 as a treatment for migraine, the potential for tezampanel to offer a unique approach to the management of pain, the potential for tezampanel or NGX426 to offer a unique approach to the management of pain and the potential timing, development and initiation of future clinical trials of tezampanel and NGX426. Such statements are subject to numerous risks, and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory approval and commercialization, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether the results of the Phase I trial are predictive of results in subsequent trials of tezampanel or NGX426, whether further testing of tezampanel and NGX426 will result in data sufficient to support regulatory approval, whether AMPA/kainate antagonists will prove to be safe and effective treatments for migraine and other pain conditions as well as non-pain conditions, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
4. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
5. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
11. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... 2013 Faruqi & Faruqi, LLP, a ... securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" or ... http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses ... federal securities laws by issuing materially false and/or ... trials for Tivopath (tivozanib) (titled "TIVO-1").  Specifically, the ...
(Date:5/17/2013)...  Lakeland Industries, Inc. (NASDAQ: LAKE ), ... healthcare and to first responders on the federal, state ... the fiscal 2013 fourth quarter and year ended January ... market close and will conduct a conference call on ... (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) The call ...
(Date:5/17/2013)... , May 17, 2013  Technology advances ... communicate internally. Faced with a constantly evolving communication ... and tactics for communicating with internal executives. It ... all the strategies, tactics and tools that are ... In a new study, Best Practices, LLC explores ...
Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness 2
... 30, 2011 Public Citizen filed a petition with the ... should revise its rules that bar generic drug makers from ... should be allowed to ask the FDA to change a ... who take their drugs. Reporters developing a story might wish ...
... Investments, Inc. ("MGT", "we", or "the Company") (AMEX: MGT.BC), a ... that NYSE Amex, LLC (the "Exchange") has accepted the Company,s ... notice from the Exchange Staff dated June 8, 2011 indicating ... listing standards as set forth in Part 10 of the ...
Cached Medicine Technology:MGT Capital Investments, Inc.'s Plan of Compliance Accepted by NYSE AMEX, LLC 2MGT Capital Investments, Inc.'s Plan of Compliance Accepted by NYSE AMEX, LLC 3
(Date:5/20/2013)... 20, 2013 Healing Heart Urgent Care ... office on Briarcliff Road in the Druid Hills neighborhood ... includes Dr. Fidias E. De León M.D. and a ... provide extensive medical services, occupational health, chiropractic care and ... metropolitan area. They also offer a full range of ...
(Date:5/20/2013)... 2013 InVite® Health, a leading nutraceutical ... introduction of its new Greens Hx™ product; ... nutrition with plant extracts from 39 super foods including ... apple pectin, plant enzymes and non-dairy probiotics. A ... antioxidant levels of several servings of vegetables. The product ...
(Date:5/20/2013)... 20, 2013 FixturesAndDisplays.com, the leading online ... of high-quality retail clothing display options to clients ranging ... retailers. Their expansive product line includes metal rack ... of mannequin options. Recently the firm ... popular models in reformulated “green” versions. These display ...
(Date:5/20/2013)... 20, 2013 As a mother to three children, ... balance family, work, and a fit, healthy lifestyle. She also knows ... hit me like a ton of bricks about a year after ... one morning and realized I had lost control of my health ... I had little to no energy to care for my sweet ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Today is ... Perfect Interview Answers Webinar tomorrow. Job seekers ... Career Confindential’s expert career coach, will show job seekers ... Webinar attendees will also learn the perfect interview answers ... as interview techniques that will get them hired. Job ...
Breaking Medicine News(10 mins):Health News:Healing Heart Urgent Care Opens New Office In Atlanta 2Health News:InVite® Health Introduces New Food-Based Dietary Supplement – Greens Hx™ 2Health News:InVite® Health Introduces New Food-Based Dietary Supplement – Greens Hx™ 3Health News:FixturesAndDisplays.com Offers Line of ‘Green’ Mannequins for Retail Displays 2Health News:FixturesAndDisplays.com Offers Line of ‘Green’ Mannequins for Retail Displays 3Health News:New Program Helps Busy Moms Become Healthier, Lose Weight, and Feel Great 2Health News:Today Is the Last Day to Register for Tomorrow’s Perfect Interview Answers Webinar From Career Confidential 2
... rank facilities don,t take all measurements into account , TUESDAY, ... onto the U.S. News & World Report list ... in some measurements regarding heart failure, researchers say. , "If ... the areas of heart failure mortality and readmission, you should ...
... be done up to 21 hours later with milder heart ... Many people who arrive at hospital emergency rooms with chest ... angioplasty, even if an electrocardiogram (EKG) shows evidence of a ... no significant difference in key measures of heart damage and ...
... 1 Zimmer Holdings, Inc. (NYSE: ZMH ; SWX: ZMH) announced ... of September: , , , Thomas ... 11:30 a.m. Eastern Time; , Morgan Stanley Healthcare Unplugged ... Eastern Time; and , UBS Global Life Sciences Conference ...
... , , , ... Hospital has earned the U.S. Environmental Protection Agency,s (EPA,s) prestigious ... environmental protection. St. Anthony,s is the first hospital in Florida ... achieve this recognition. Buildings that receive the EPA,s ENERGY STAR ...
... CHSI Solutions Hotline Provides NRSIG Members Immediate Medical Assessment -- ... September 1, 2009, employees of Nevada Restaurant Self-Insured Group members injured ... assessment from a medical professional when they call the CHSI Solutions ... Hotline will be available to NRSIG members and their employees all ...
... , , , ... an operating subsidiary of WellPoint, Inc. (NYSE: WLP ) and one ... on diagnostic imaging that appear in the August 27, 2009 issue of the ... article "Exposure to Low-Dose Ionizing Radiation from Medical Procedures" reviews the ...
Cached Medicine News:Health News:Government Best Source for U.S. Hospital Data, Study Finds 2Health News:Sometimes Angioplasty Can Wait 2Health News:St. Anthony's Hospital Is First to Earn EPA'S ENERGY STAR(R) Symbol for Superior Energy Efficiency 2Health News:St. Anthony's Hospital Is First to Earn EPA'S ENERGY STAR(R) Symbol for Superior Energy Efficiency 3Health News:Nevada Restaurant Self-Insured Group Launches 24-Hour Injury Hotline on September 1 to Ensure Employee Safety 2Health News:American Imaging Management Reacts to New England Journal of Medicine Articles on Diagnostic Imaging 2
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... a complete line of enteric ... monoclonal and monoclonal/polyclonal antibody-based ELISA ... enteric pathogens in fecal specimens. ... Clostridium difficile, Entamoeba histolytica, Giardia, ...
Inquire...
Medicine Products: